Glucose tolerance (GT)

Glucose tolerance refers to the physiological capacity of an organism to regulate blood glucose levels following the ingestion or injection of a glucose load [1]. It is not a single molecular target like a receptor or enzyme, but rather a complex metabolic outcome mediated by the coordinated interplay between insulin secretion from pancreatic beta cells and the insulin sensitivity of peripheral tissues such as the liver, skeletal muscle, and adipose tissue [2, 3]. Impaired glucose tolerance (IGT) is a pre-diabetic clinical state characterized by blood glucose levels that are higher than normal but below the threshold for a diabetes diagnosis, serving as a significant risk factor for cardiovascular disease [4]. Therapeutic agents do not target 'glucose tolerance' as a molecule; instead, they interact with specific proteins like the Glucagon-like peptide 1 receptor (GLP1R) or Sodium-glucose cotransporter 2 (SGLT2) to improve the body's overall glycemic control [5]. Monitoring glucose tolerance through standardized tests is a cornerstone for diagnosing metabolic disorders and assessing the efficacy of pharmacological interventions in clinical practice [1, 2]. Sources: [1] StatPearls, 'Glucose Tolerance Test' (https://www.ncbi.nlm.nih.gov/books/NBK532939/) [2] NIH National Institute of Diabetes and Digestive and Kidney Diseases, 'Insulin Resistance & Prediabetes' (https://www.niddk.nih.gov) [3] Nature Reviews Endocrinology, 'Regulation of glucose homeostasis' (https://www.nature.com/nrendo/) [4] World Health Organization, 'Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia' (https://www.who.int) [5] American Diabetes Association, 'Pharmacologic Approaches to Glycemic Treatment' (https://diabetesjournals.org/care)

Other names

Glucose homeostasisGlycemic controlGlucose disposalImpaired glucose tolerance (IGT)Glucose clearance

Drugs improve glucose tolerance by acting on specific molecular targets to enhance insulin sensitivity (e.g., Metformin via AMPK), stimulate insulin secretion (e.g., GLP-1 agonists), slow carbohydrate absorption (e.g., Alpha-glucosidase inhibitors), or increase renal glucose excretion (e.g., SGLT2 inhibitors).